Browsing Tag
Repare Therapeutics
3 posts
Repare Therapeutics (NASDAQ: RPTX) investors back acquisition by nonprofit XenoTherapeutics; court approval pending
Repare shareholders approve Xeno acquisition; cash payout rises to $2.20 after Gilead deal. Find out what this means for biotech investors and rivals.
Gilead Sciences acquires RP-3467 from Repare Therapeutics to strengthen synthetic lethality pipeline
Gilead buys RP-3467 from Repare for up to $30M, boosting Repare’s shareholder payout ahead of its Xeno acquisition. Find out what this means for oncology.
Repare Therapeutics (RPTX) to be acquired by XenoTherapeutics in CVR-backed buyout
Repare Therapeutics to be acquired by XenoTherapeutics with $1.82/share cash payout and long-term CVR upside. Find out what this means for investors.